Cenicriviroc
Encyclopedia
Cenicriviroc is an experimental drug candidate for the treatment of HIV
infection. It is being developed by Takeda Pharmaceutical and Tobira Therapeutics.
Cenicriviroc is an inhibitor of CCR2
and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell.
A double-blind, randomized, placebo-controlled clinical study to assess the antiviral activity, safety, and tolerability of cenicriviroc was conducted in 2010. HIV-infected patients taking cenicriviroc had significant reductions in viral load, with the effect persisting up to two weeks after discontinuation of treatment. Additional Phase II clinical trials are underway.
HIV
Human immunodeficiency virus is a lentivirus that causes acquired immunodeficiency syndrome , a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive...
infection. It is being developed by Takeda Pharmaceutical and Tobira Therapeutics.
Cenicriviroc is an inhibitor of CCR2
CCR2
CCR2, short for chemokine receptor 2, is a chemokine receptor.CCR2 has also recently been designated CD192 .-External links:* at...
and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell.
A double-blind, randomized, placebo-controlled clinical study to assess the antiviral activity, safety, and tolerability of cenicriviroc was conducted in 2010. HIV-infected patients taking cenicriviroc had significant reductions in viral load, with the effect persisting up to two weeks after discontinuation of treatment. Additional Phase II clinical trials are underway.
See also
- Discovery and development of CCR5-receptor antagonists
- MaravirocMaravirocMaraviroc is an antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. It is also classed as an entry inhibitor.-Mechanism of action:...
- VicrivirocVicrivirocVicriviroc, previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1. It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy...